When.com Web Search

Search results

  1. Results From The WOW.Com Content Network
  2. Discussion of Diagnosis Renal anemia is ... the possibilities of recombinant erythropoietin overdosing and disorders such as neoplasms and polycythemia vera must be excluded. ...

  3. December 8, 2012 — Atlanta, GA — Maintaining a lower hematocrit (HCT) can help lower the risk for cardiovascular (CV) death in patients with polycythemia vera, according to the results of a ...

  4. Diagnosis requires meeting all four criteria: Hct = Hematocrit; Hgb = Hemoglobin; PMF = Primary myelofibrosis. ... However, while almost 100% of polycythemia vera (PV) patients have a molecular ...

  5. Diagnosis requires meeting all four criteria: Hct = Hematocrit; Hgb = Hemoglobin; PMF = Primary myelofibrosis. ... However, while almost 100% of polycythemia vera (PV) patients have a molecular ...

  6. Hepatic Vein Thrombosis - Page 3 - Medscape

    www.medscape.com/viewarticle/430203_3

    [18,20,28] Conventionally, diagnosis of overt myeloproliferative disease requires several criteria to be met, including elevated red cell or platelet counts. In patients with the occult forms ...

  7. Polycythemia Vera As outlined previously, approximately 25 years ago the first report on IFN-α in PV was described by the Austrian group documenting the efficacy and tolerability of low or ...

  8. Williams: Right, it should raise your eyebrows a little bit.The thing that we think about classically is polycythemia vera.We touched on physical exam tips and the history. In terms of looking at ...

  9. Polycythemia is also associated with hypertension due to increased blood viscosity and thrombosis. Severe, chronic polycythemia secondary to increased blood viscosity can raise pulmonary arterial ...

  10. Aspirin effective for polycythemia vera - Medscape

    www.medscape.com/viewarticle/784981

    Primary prevention study of aspirin in polycythemia vera. In the study, which was conducted via a network of 94 hematologic centers in 12 European countries, 253 patients were randomized to 100 mg ...

  11. The European Medicines Agency has recommended this month that ruxolitinib be approved to treat polycythemia vera. Rituximab is an oral inhibitor of the Jak 1 and Jak 2 tyrosine kinases.